Insilico Opens AI Longevity Toolkit to Researchers, Outperforming Frontier Models — Insilico Medicine Inc.

Event summary

Insilico Medicine published a study in Cell on September 17, 2026, introducing an open AI toolkit for longevity research, including LongevityBench, Longevity-LLMs, and Longevity Claw.
LongevityBench is the first open benchmark designed to evaluate AI reasoning across multiple domains of aging biology.
Longevity-LLMs, a family of compact, open-source language models, outperformed 16 frontier AI systems in the study.
Longevity Claw, an autonomous research platform, nominated 328 genes as potential targets for aging intervention.
Insilico reported $106 million in revenue for the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year since listing.

The big picture

Insilico Medicine's open AI toolkit represents a strategic shift in longevity research, providing a common foundation for evaluating AI systems in aging biology. The company's ability to outperform frontier models with compact, specialized language models challenges the dominance of large-scale AI systems in scientific applications. Insilico's recent financial performance and extensive partnerships underscore its position as a key player in AI-driven drug discovery and longevity interventions.

What we're watching

Model Performance: Whether Insilico's compact Longevity-LLMs can sustain their performance advantage over frontier models in real-world applications.
Research Adoption: The pace at which the scientific community adopts and validates Insilico's open AI toolkit for longevity research.
Commercialization: How Insilico plans to monetize its AI-driven drug discovery capabilities beyond current partnerships.